Tags

Type your tag names separated by a space and hit enter

Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.
Muscle Nerve. 2016 06; 54(1):142-4.MN

Abstract

INTRODUCTION

Patients with self-limited statin-related myopathy improve spontaneously when statins are stopped. In contrast, patients with statin-associated autoimmune myopathy have autoantibodies recognizing 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) and usually require immunosuppressive therapy to control their disease. On initial presentation, it can sometimes be difficult to distinguish between these 2 diseases, as both present with muscle pain, weakness, and elevated serum creatine kinase (CK) levels. The goal of this study was to determine whether patients with severe self-limited statin-related myopathy also make anti-HMGCR autoantibodies.

METHODS

We screened 101 subjects with severe self-limited cerivastatin-related myopathy for anti-HMGCR autoantibodies.

RESULTS

No patient with severe self-limited cerivastatin-related myopathy had anti-HMGCR autoantibodies.

CONCLUSION

Anti-HMGCR autoantibody testing can be used to help differentiate whether a patient has self-limited myopathy due to cerivastatin or autoimmune statin-associated myopathy; these findings may apply to other statins as well. Muscle Nerve 54: 142-144, 2016.

Authors+Show Affiliations

Department of Medicine, University of Washington, Seattle, Washington, USA.Department of Medicine, University of Washington, Seattle, Washington, USA.Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.Department of Medicine, University of Washington, Seattle, Washington, USA. Department of Epidemiology, University of Washington, Seattle, Washington, USA. Health Services, University of Washington, Seattle, Washington, USA.Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. National Institutes of Health, Bethesda, Maryland, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

27038110

Citation

Floyd, James S., et al. "Absence of anti-HMG-CoA Reductase Autoantibodies in Severe Self-limited Statin-related Myopathy." Muscle & Nerve, vol. 54, no. 1, 2016, pp. 142-4.
Floyd JS, Brody JA, Tiniakou E, et al. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve. 2016;54(1):142-4.
Floyd, J. S., Brody, J. A., Tiniakou, E., Psaty, B. M., & Mammen, A. (2016). Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle & Nerve, 54(1), 142-4. https://doi.org/10.1002/mus.25127
Floyd JS, et al. Absence of anti-HMG-CoA Reductase Autoantibodies in Severe Self-limited Statin-related Myopathy. Muscle Nerve. 2016;54(1):142-4. PubMed PMID: 27038110.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. AU - Floyd,James S, AU - Brody,Jennifer A, AU - Tiniakou,Eleni, AU - Psaty,Bruce M, AU - Mammen,Andrew, PY - 2016/03/28/accepted PY - 2016/4/3/entrez PY - 2016/4/3/pubmed PY - 2017/6/24/medline KW - adverse drug reaction KW - autoimmune KW - myopathy KW - rhabdomyolysis KW - statins SP - 142 EP - 4 JF - Muscle & nerve JO - Muscle Nerve VL - 54 IS - 1 N2 - INTRODUCTION: Patients with self-limited statin-related myopathy improve spontaneously when statins are stopped. In contrast, patients with statin-associated autoimmune myopathy have autoantibodies recognizing 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) and usually require immunosuppressive therapy to control their disease. On initial presentation, it can sometimes be difficult to distinguish between these 2 diseases, as both present with muscle pain, weakness, and elevated serum creatine kinase (CK) levels. The goal of this study was to determine whether patients with severe self-limited statin-related myopathy also make anti-HMGCR autoantibodies. METHODS: We screened 101 subjects with severe self-limited cerivastatin-related myopathy for anti-HMGCR autoantibodies. RESULTS: No patient with severe self-limited cerivastatin-related myopathy had anti-HMGCR autoantibodies. CONCLUSION: Anti-HMGCR autoantibody testing can be used to help differentiate whether a patient has self-limited myopathy due to cerivastatin or autoimmune statin-associated myopathy; these findings may apply to other statins as well. Muscle Nerve 54: 142-144, 2016. SN - 1097-4598 UR - https://www.unboundmedicine.com/medline/citation/27038110/Absence_of_anti_HMG_CoA_reductase_autoantibodies_in_severe_self_limited_statin_related_myopathy_ L2 - https://doi.org/10.1002/mus.25127 DB - PRIME DP - Unbound Medicine ER -